Skip to main navigation Skip to search Skip to main content

Plasma Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an 18-Month-Old Heart Transplant Recipient: Case Report and Review of the Literature

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Plasma cell myeloma type posttransplant lymphoproliferative disorder (PTLD) is a rare subtype of monomorphic B-cell/ plasmacytic-type PTLD. Only 10 cases of monomorphic plasmacytic-type PTLD have been previously reported in pediatric transplant recipients (kidney, liver, small bowel-liver, and heart). We present a case of Epstein-Barr virus positive monomorphic plasma cell myeloma type PTLD that developed 10 months after cardiac transplant in an 18-month-old boy. The bone marrow showed replacement by about 20% to 40% lambda-restricted plasmacytoid lymphocytes and plasma cells (by immunohistochemistry and flow cytometry, respectively). His serum free lambda to kappa light chain ratio was > 300, comparable to that seen in myeloma in nontransplant patients. The neoplastic cells were Epstein-Barr virus small RNA positive by in situ hybridization. He was treated with rituximab in combination with ganciclovir, intravenous immune globulin, and discontinuation of immunosuppressants. However, he succumbed to septic shock and multiorgan failure 1 month after diagnosis.

    Original languageEnglish
    Pages (from-to)E170-E173
    JournalJournal of Pediatric Hematology/Oncology
    Volume42
    Issue number3
    DOIs
    StatePublished - Apr 1 2020

    ASJC Scopus Subject Areas

    • Pediatrics, Perinatology, and Child Health
    • Hematology
    • Oncology

    Keywords

    • Childhood
    • Epstein-Barr virus
    • Heart transplant
    • Monomorphic B-cell PTLD
    • Plasma cell myeloma type
    • Posttransplant lymphoproliferative disorder (PTLD)
    • Humans
    • Multiple Myeloma/immunology
    • Heart Transplantation
    • Infant
    • Male
    • Transplant Recipients
    • Fatal Outcome
    • Epstein-Barr Virus Infections/complications
    • Immunocompromised Host

    Cite this